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    OBJECTIVES:       VSL  #  3 is a high-potency probiotic mixture that has been used successfully in the treatment of 
pouchitis. The primary end point of the study was to assess the effects of supplementation with 
VSL  #  3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 
5-aminosalicylic acid (ASA) and  /  or immunosuppressants at stable doses. 
    METHODS:       A total of 144 consecutive patients were randomly treated for 8 weeks with VSL  #  3 at a dose of 
3,600 billion CFU  /  day (71 patients) or with placebo (73 patients). 
    RESULTS:       In all, 65 patients in the VSL  #  3 group and 66 patients in the placebo group completed the study. 
The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50  %   or more was higher in 
the VSL  #  3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP)   P         =     0.010, conﬁ  dence 
interval (CI)  95  %    0.51   –  0.74; intention to treat (ITT)   P         =     0.031, CI  95  %    0.47   –  0.69). Signiﬁ  cant results 
with VSL  #  3 were recorded in an improvement of three points or more in the UCDAI score (60.5  %   
vs. 41.4  %  ; PP   P          =     0.017, CI  95  %    0.51   –  0.74; ITT   P         =     0.046, CI  95  %    0.47   –  0.69) and in rectal bleeding 
(PP   P         =     0.014, CI  95  %    0.46   –  0.70; ITT   P         =     0.036, CI  95  %    0.41   –  0.65), whereas stool frequency 
(PP   P         =     0.202, CI  95  %    0.39   –  0.63; ITT   P         =     0.229, CI  95  %    0.35   –  0.57), physician  ’  s rate of disease 
activity (PP   P         =     0.088, CI  95  %    0.34   –  0.58; ITT   P         =     0.168, CI  95  %    0.31   –  0.53), and endoscopic scores 
(PP   P         =     0.086, CI  95  %    0.74   –  0.92; ITT   P         =     0.366, CI  95  %    0.66   –  0.86) did not show statistical differences. 
Remission was higher in the VSL  #  3 group than in the placebo group (47.7  %   vs. 32.4  %  ; PP   P         =     0.069, 
CI  95  %    0.36   –  0.60; ITT   P         =     0.132, CI  95  %    0.33   –  0.56). Eight patients on VSL  #  3 (11.2  %  ) and nine 
patients on placebo (12.3  %  ) reported mild side effects. 
    CONCLUSIONS:       VSL  #  3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing 
mild-to-moderate UC who are under treatment with 5-ASA and  /  or immunosuppressants. Moreover, 
VSL  #  3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 
8 weeks of treatment, although these parameters do not reach statistical signiﬁ  cance.   
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  Probiotics for Relapsing Ulcerative Colitis 
  INTRODUCTION 
  Ulcerative colitis (UC) is a chronic infl  ammatory disease of the 
colon characterized by bloody diarrhea and abdominal pain. 
Despite recent advances in the understanding of the genetics, 
immune and infl   ammatory mechanisms, as well as potential 
environmental factors that contribute to the disease, an exact 
pathogenesis remains elusive. Hence, the treatment is aimed at 
modifying the pathogenic mechanisms involved, mostly by using 
anti-infl   ammatory drugs such as mesalazine, corticosteroids, 
immunosuppressant agents, or biologics (  1  ). 
  Recently, modulation of the gut fl  ora has been suggested as an 
approach to manage UC. Th   e role of microbiome in infl  ammatory 
bowel disease is clearly supported by many experimental observa-
tions. Gut fl  ora can be modifi  ed either by antibiotics or by probiot-
ics. Antibiotics are not good candidates for patients with chronic 
disorders because of antibiotic resistance, potential side eff  ects, 
and ecological concerns. 
 Probiotics have proven to be eff  ective in the management of pou-
chitis (  3,4  ), and preliminary data are available for the treatment of 
UC (  5,6  ), but strong data are still lacking in both UC and Crohn  ’  s 
disease. In particular, there is limited evidence that probiotics, in 
addition to standard therapy, may provide benefi  ts in terms of 
reduction of disease activity in patients with mild to moderately 
active UC because of a lack of well-designed, large, randomized, 
placebo-controlled trials (  7  ). 
 Th  e present study has been conducted with VSL  #  3, a product 
that has proven to be eff  ective for the treatment and prevention of 
pouchitis  ( 3 ).  Th   e aim of this investigation was to assess whether, 
by adding VSL # 3 to the current standard treatment of patients with 
mild-to-moderate UC, it would be possible to decrease the ulcera-
tive colitis disease activity index (UCDAI) score by at least 50  %   
and improve some of the symptoms associated with UC. Positive 
results would encourage a new approach in managing UC patients 
to avoid or delay step-up therapies with drugs burdened by poten-
tially serious side eff  ects.     
  METHODS 
  A multicenter, double-blind, randomized, placebo-controlled, 
parallel study was conducted in a population of UC patients with 
relapsing disease of mild-to-moderate severity. 
 We defi   ned  “ relapsing mild-to-moderate UC ”  as a disease show-
ing symptomatic recurrence aft  er at least 6 months of remission 
(  8  ), with a new increase in UCDAI (see   Table 1  ) of at least three 
points (between three and eight) (  9  ). 
 Th   e protocol was approved by the Investigational Review Board 
of each center. All patients gave written informed consent for their 
participation.  
  Sample size 
 Th  e sample size was based on a power of 80  %   and a statistical 
signifi  cance (  α )  of  95 %   ( P     =    0.05).  Th   is calculation was based on 
the assumption that a response to treatment at 8 weeks, such as 
with oral 5-aminosalicylic acid (ASA) preparations, was expected 
to occur in 71  %   of patients treated with VSL  #  3 compared with 
a 40  %   expected response for patients treated with placebo. Th  is 
assumed that the probiotic is as eff  ective as oral 5-aminosalycilic 
acid. Th   erefore, 59 patients were required in each group, with an 
additional 15 %  for dropouts and 5 %  for patients failing to undergo 
fi  nal endoscopic assessment; hence a total of 144 patients were 
planned for the trial.     
  Study procedures 
 Th  e study procedures were conducted for each patient enrolled 
in the study. 
 At the screening visit, each patient ’ s demographic characteristics, 
medical history, and current medications were recorded.   β -Chori-
onic gonadotropin hormone was also assessed in women of child-
bearing age and was collected and analyzed to exclude pregnancy. 
  Eligible patients were randomly assigned to receive either VSL  #  3 
or placebo twice daily for 8 weeks. Th   e study product, VSL  #  3, was 
provided in plastic sealed individual dose sachets. Placebo was sup-
plied in identical sachets. Patients were asked to take the contents of 
the sachets in the morning and evening. Individual disease activity 
quantifi  ed by the patient  ’  s UCDAI was calculated. Th   e UCDAI was 
calculated by the investigator, who added the individual scores of the 
four parameters (bowel frequency, rectal bleeding, endoscopic score, 
and physician  ’  s rating of severity). At each visit, a detailed physical 
    Table 1  .       Ulcerative colitis (UC) disease activity index     
        1. Stool frequency      
           Normal   0 
           1  –   2 Stools /  day      >      normal   1 
           3   –  4 Stools /  day      >      normal   2 
                 >      4 Stools  /  day      >      normal   3 
        2. Rectal bleeding      
           None   0 
           Streaks of blood    1 
           Obvious blood    2 
           Mostly blood    3 
        3. Mucosal appearance      
           Normal   0 
           Mild friability    1 
           Moderate friability    2 
           Exudation, spontaneous bleeding    3 
        4. Physician’s rating of disease activity      
           Normal   0 
           Mild   1 
           Moderate   2 
           Severe   3 
          The index assesses four variables, which include stool frequency, severity of 
bleeding, colonic mucosal appearance, and the physician’s overall assessment 
of disease activity.     
          Each variable is scored from 0   –  3 so that the total index score ranges from 0   –  12; 
0  –   2: remission; 3   –  6: mild; 7  –  10: moderate;       >      10: severe UC.     The American Journal of GASTROENTEROLOGY  VOLUME 105 | OCTOBER 2010   www.amjgastro.com
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examination and history were performed. All adverse events were 
documented, classifi  ed, and graded. Study participants were supplied 
with diary cards to assess and record their symptoms (stool frequency, 
bleeding, and abdominal pain) on a daily basis. Participants  ’   com-
pliance was assessed by the investigators, who counted the unused 
sachets that the patients were requested to bring back at week 8.     
  Inclusion criteria 
  Patients had to meet all the inclusion criteria described in   Table 2  
to be eligible for participation. Moreover, women who had a nega-
tive pregnancy test at the screening visit and agreed to use a valid 
contraceptive method for the duration of the study, as well as 
patients not requiring hospitalization and patients willing and able 
to provide written informed consent, were considered eligible for 
inclusion in the study.     
  Exclusion criteria 
  Patients who met any of the exclusion criteria as described in 
  Table 3   were not enrolled in this study. 
 Signifi  cant hepatic, renal, endocrine, respiratory, neurological, 
or cardiovascular diseases, as determined by the investigator, were 
also considered as exclusion criteria. Other exclusion criteria that 
were also taken into consideration included the following:     
  a history of severe adverse reaction or known hypersensitivity 
to maltose and  /  or silicon dioxide; 
  patients requiring hospitalization; 
  use of any investigational drug and  /  or participation in any 
clinical trial within 3 months before entering this study; 
 inability to give a valid written informed consent or to properly 
follow  the  protocol.     
  Treatment 
  Patients meeting the inclusion criteria were randomly assigned 
to one of the two groups of treatment and received the product 
•
•
•
•
for 8 weeks in addition to their standard pharmaceutical therapy 
(5-ASA  and / or  immunosuppressant).  VSL # 3  consists  of  sachets, 
each containing 900 billion viable lyophilized bacteria, com-
prising four strains of lactobacilli (  L. paracasei ,   L. plantarum , 
  L. acidophilus  , and   L. delbrueckii   subsp   bulgaricus  ), three strains 
of bifi  dobacteria (  B. longum ,   B. breve  , and   B. infantis  ), and one 
strain of   Streptococcus thermophilus   (VSL Pharmaceuticals, MD). 
Th   e daily dose was two sachets twice a day taken orally (3,600 billion 
bacteria per day). Th   e patient was asked to mix the contents of the 
sachets in a glass of cold water or in yogurt. Hot beverages were 
excluded, as an elevated temperature may inactivate the bacteria. 
Th   e placebo was in the form of identical sachets that did not contain 
any lyophilized bacteria.     
  Concomitant treatments 
  Patients who were taking maintenance oral 5-ASA and  /  or 
azathioprine or 6-mercapropurine continued to do so at sta-
ble doses. Th  e 5-ASA doses had to be fi  xed for 4 weeks and 
azathioprine or 6-mercaptopurine doses were fi  xed for at least 
3 months before study entry, and had to be maintained at the 
same dose throughout the study. Any change in dosing of oral 
5-ASA or in dosing of oral 6-mercaptopurine and azathioprine 
drugs throughout the 8-week study period was considered as a 
protocol violation. 
 Rectally administered medications, steroids, antibiotics, probiot-
ics, and antidiarrheal drugs were not allowed, nor were any fruits, 
vegetables, milk, or fresh milk by-products. 
 VSL # 3 supplementation had to be interrupted for a minimum of 
14 days before inclusion in the study.     
  Primary end point 
 Th   e primary end point was the evaluation of the benefi  cial eff  ects 
of food supplementation with VSL # 3 in relapsing mild-to-moder-
ate UC patients, assessed by a decrease in the UCDAI of 50  %   or 
more, from baseline to week 8.     
    Table 2  .       Inclusion criteria     
      Male and female patients aged more than 18 years; 
      Diagnosis of UC established by previous colonoscopy, with consistent 
histology and clinical course; 
      UC involving at least the rectosigmoid region; activity conﬁ  rmed by 
colonoscopy at the beginning of the study; 
      Mild-to-moderate relapsing UC, deﬁ  ned as a UCDAI score ranging from 
three to eight; 
      Symptoms (relapsing episodes) for less than 4 weeks before study entry; 
      A minimum endoscopic score of three on the UCDAI at screening 
(mucosal appearance); 
      Use of oral 5-ASA at least 4 weeks before study entry at a stable dose 
(mesalazine at least 1.6 g  /  day or balsalazide at least 4.5 g  /  day) and  /  or use 
of azathioprine (at least 1.5 mg  /  kg  /  day) or 6-mercaptopurine (at least 
1 mg  /  kg  /  day) at least 3 months before study entry at a stable dose. 
          ASA, aminosalicylic acid; UC, ulcerative colitis; UCDAI, ulcerative colitis disease 
activity index.     
    Table 3  .       Exclusion Criteria     
      Crohn’s disease or pouchitis; 
      A UCDAI score greater than eight (need for emergency surgery or the 
presence of severe disease); 
      Use of oral steroids within the last 4 weeks before study entry; 
      Use of antibiotics within the last 2 weeks before study entry; 
      Change in dose of oral 5-ASA within the last 4 weeks before study entry 
and throughout the 8-week study period or a change in dose of oral 
6-mercaptopurine and azathioprine drugs within the last 3 months before 
the study; 
      Use of rectal 5-ASA or steroids within 1 week before entering the study or 
throughout the 8-week study period; 
      Use of probiotic preparations either prescribed or over-the-counter within 
2 weeks before study entry; 
      Use of NSAIDs for 1 week before and throughout the 8-week study period. 
          ASA, aminosalicylic acid; NSAID, non-steroidal anti-inﬂ  ammatory drug; UCDAI, 
ulcerative colitis disease activity index.     © 2010 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Probiotics for Relapsing Ulcerative Colitis 
  Secondary end points 
 Secondary end points were the possible benefi  cial eff  ects of VSL # 3 
on the following:     
  activity of relapsing UC; 
  remission, considered as UCDAI   ≤  2, assessed at week 8; 
  improvement in endoscopic scores, assessed by the endo-
scopic subgroup score of the UCDAI at week 8; 
  change in objective symptoms (rectal bleeding and stool 
frequency); 
  change in subjective symptoms (physician rating of disease 
activity); 
 lack  of  benefi  cial eff  ects, defi  ned by the need for pharmaco-
logical treatment or inability to remain on the study regimen 
until  week  8.     
  Randomization 
  Each center enrolled patients according to the randomization 
list. Patients who fulfi  lled the eligibility criteria specifi  ed above 
were randomly assigned to receive VSL  #  3 or placebo in a ran-
dom order, using only one randomization list. Th  e  randomization 
number was strictly given according to the order of the patient  ’  s 
enrollment, assigning each patient the fi  rst available number on 
the randomization list. Th   e randomization number, or the reason 
for not enrolling the patient, was reported for each patient in the 
appropriate forms. Randomization was carried out in a double-
blind manner in blocks of four patients using 1:1 allocation to the 
two  groups.   
  Assessment of compliance 
 Th   e investigators assessed compliance by checking the number of 
unused sachets that the patients brought back at each visit.     
  Statistical assessment 
  Baseline characteristics of patients were compared using Student  ’  s 
  t  -test for independent samples or Pearson  ’  s   χ  2 -test  as  appropriate. 
•
•
•
•
•
•
Values of  P   ≥ 0.05 were considered statistically signifi   cant. Pearson ’ s 
  χ  2  -test was used to compare the UCDAI score at each visit with the 
basal visit score aft  er adjustment of data using the last-observation-
carried-forward method. Comparison of stool frequency, rectal 
bleeding, and mucosal appearance at each time between treat-
ment groups and at each visit vs. the basal value was performed 
using  Pearson ’ s   χ  2 -test.  Th   e  95 %   confi  dence interval (CI) was also 
assessed. 
  A multivariate analysis was also performed. Th   e general linear 
model multivariate procedure is based on a general linear model 
in which factors and covariates are assumed to have linear rela-
tionships to the dependent variables. As dependent variables, we 
chose UCDAI overall response at visit three (increase of 50  %   or 
more in the UCDAI score compared with the screening score) and 
disease extension at visit three (left  -sided colitis, distal colitis, pan-
colitis). Fixed factors categorical predictors were selected as factors 
in the model (treatment with placebo or VLS  #  3, and concomitant 
treatment with or without the combination of 5-ASA and immu-
nosuppressors). Th   e general linear model multivariate procedure 
assumes that all model factors are fi  xed, i.e., they are generally 
thought of as variables, the values of interest of which are all repre-
sented in the data fi  le, usually by design. 
 Th   e statistical analysis of all the data sets pertaining to effi   -
cacy (specifi  cally, primary and secondary end points) and safety 
(specifi  cally, serious adverse events as defi  ned by federal guide-
lines) has been independently performed by a biostatistician 
who is not employed by the corporate entity. Th  e  corresponding 
author had full access to all data and takes full responsibility for 
the veracity of the data and analysis.       
  RESULTS   
  Participant ﬂ  ow 
  A total of 144 patients (71 in the VSL  #  3 group and 73 in the pla-
cebo group) were enrolled. No patient was withdrawn before 
treatment assignment (see   Figure 1 ).   
Patients entered
144
Patients randomized
144
Full analysis set
144
Patients not included
in the full analysis set
0
Patients discontinued
6
Patients discontinued
7
Patients completed
65
Placebo
73
VSL#3
71
Patients completed
66
    Figure 1  .                 Patient disposition.   The American Journal of GASTROENTEROLOGY  VOLUME 105 | OCTOBER 2010   www.amjgastro.com
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  Six patients in the VSL  #  3 group withdrew during the follow-
up, two had protocol violations (these patients took beclom-
etasone dipropionate and prednisone), two withdrew their 
informed consent, and three were lost to follow-up. Among the 
seven patients in the placebo group who withdrew during the 
follow-up, fi  ve patients experienced a worsening of symptoms, 
one was lost to follow-up, and one withdrew informed consent 
(see   Table 6 ).   
  Primary end point 
 Overall,  VSL # 3  was  signifi  cantly superior to placebo in reduc-
ing the disease activity of mild-to-moderate UC. Signifi  cantly 
more patients in the VSL  #  3 group experienced an improvement 
in their UCDAI score of at least 50  %   at the end of 8 weeks than 
those who received the placebo (41 (63.1  %  ) vs. 29 (40.8  %  ), 
respectively; PP   P     =    0.010,  CI 95 %    0.51 – 0.74;  ITT   P     =    0.031,  CI 95 %   
0.47 – 0.69)  (see   Figure 2 ). 
 To evaluate a more homogeneous set of patients, we also excluded 
patients who were under immunosuppressive treatment from 
the fi  nal evaluation. However, no statistical diff  erence was found 
because VSL  #  3 was still signifi  cantly better in improving UCDAI 
scores of at least 50 %  at the end of 8 weeks than placebo (37 (56.1 % ) 
vs. 25 (36.2  %  ), respectively; PP   P     =    0.008;  ITT   P     =    0.025).   
  Secondary end points 
 Similarly,  a  signifi  cantly higher number of patients in the VSL  #  3 
group had a decrease of three or more points in their UCDAI 
score from baseline to week 8 than the placebo group (39 (60  %  ) 
vs. 29 (43.94  %  ), respectively; PP   P     =    0.017,  CI 95 %    0.51 – 0.74;  ITT 
  P     =    0.046,  CI 95 %    0.47 – 0.69)  (see   Figure 2 ). 
  Regarding the induction of remission, 31 (47.7  %  ) patients in 
the VLS  #  3 group and 23 (32.4  %  ) patients in the placebo group 
experienced remission by the end of 8 weeks; although a   Δ   value 
of 15.3  %   was observed, this diff  erence was not statistically signifi  -
cant (PP  P     =    0.069, CI 95 %   0.36 – 0.60; ITT  P     =    0.132, CI 95 %   0.33 – 0.56) 
(see   Figure 2  ). None of the parameters assessed in the multivari-
ate analysis was found to have a signifi  cant role in infl  uencing 
remission. 
 To evaluate a more homogeneous set of patients, we also excluded 
patients under immunosuppressive treatment from the fi  nal evalu-
ation. However, no diff  erence was found because VSL  #  3 was still 
better in obtaining remission at the end of 8 weeks than placebo, 
and the result did not reach statistical signifi  cance (28 (42.4  %  ) vs. 
20 (29  %  ), respectively; PP   P     =    0.067;  ITT   P     =    0.110). 
  Baseline data 
 Th  e clinical characteristics of patients in the two groups were 
comparable (  Table 4  ). No signifi  cant diff  erences were identifi  ed 
in terms of demographic characteristics (mean age, male  –  female 
ratio, weight, height, and mean UCDAI).     
  Clinical response 
 Th   e main clinical outcomes of the study according to per-protocol 
(PP) and intention-to-treat (ITT) methods are shown in   Table 5 . 
    Table 4  .       Patient demographic and baseline characteristics     
        Characteristic       VSL  #  3       Placebo   
      Gender (male:female)    49:22 (69  %  )   44:29 (60.3  %  ) 
      Age in years (mean   ±  s.d.)   47.7   ±  14.1   46.4   ±  14.4 
      Number of previous relapses 
(mean   ±  s.d.) 
  2.24   ±  1.05   2.37   ±  1.04 
      UCDAI at entry (mean   ±  s.d.)   5.52   ±  1.33   5.42   ±  1.43 
        Disease extent (number of patients) (  %  )   
           Proctosigmoiditis   36 (50.7  %  )   38 (52.1  %  ) 
           Left-sided colitis    24 (33.8  %  )   21 (28.8  %  ) 
           Pancolitis   11 (15.5  %  )   14 (19.1  %  ) 
        Concomitant medications   
             Mesalamine alone 
(mean  /  median   ±  s.d.) 
  65 (91.55  %  ) 
(2.08  /  2.4   ±  0.39) 
  69 (94.52  %  ) 
(2.08  /  2.4   ±  0.40) 
             Balsalazide alone 
(mean  /  median   ±  s.d.) 
  2 (2.82  %  ) 
(4.5  /  4.5) 
  2 (2.74  %  ) (4.5  /  4.5) 
             Azathioprine alone 
(mean  /  median   ±  s.d.) 
  1 (1.23  %  ) 
(1.62  /  1.5   ±  0.25) 
  0 (0  %  ) 
             Methotrexate alone 
(mean  /  median   ±  s.d.) 
  1 (1.23  %  ) 
(15    mg i.m.  /  week) 
  0 (0  %  ) 
           No medications    0 (0  %  )   0 (0  %  ) 
        Combinations of drugs   
             Mesalamine      +      azathioprine 
(mean  /  median   ±  s.d.) 
  2 (3.90  %  ) 
(2.08  /  2.4   ±  0.39)      +       
(1.62  /  1.5   ±  0.25) 
  2 (2.74  %  ) 
(2.08  /  2.4    ±   0.40)      +       
1.75  /  1.75   ±  0.25 
             Balsalazide      +      azathioprine   0 (0  %  )   0 (0  %  ) 
             Balsalazide      +      methotrexate   0 (0  %  )   0 (0  %  ) 
           Total   71 (100  %  )   73 (100  %  ) 
          i.m., intra-muscular; UCDAI, ulcerative colitis disease activity index.     
    Table 5  .       Clinical outcomes     
           Per-protocol       Intention-to-treat   
           VSL  #  3       Placebo         P       value       VSL  #  3       Placebo         P       value   
        ≥  50  %   Improvement in UCDAI (week 8)    41   29   0.010   41   29   0.031 
            ≥      3 Decrease in UCDAI score (week 8)    39   29   0.017   39   28   0.046 
      Remission (week 8)    31   23   0.069   31   23   0.132 
          UCDAI, ulcerative colitis disease activity index.     © 2010 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Probiotics for Relapsing Ulcerative Colitis 
 It is interesting that  Tables 7 and 8  show that none of the patients 
in the VSL  #  3 group experienced a worsening of symptoms dur-
ing the follow-up, whereas several patients in the placebo group 
showed a worsening of symptoms, and fi  ve of them had to be with-
drawn from the study. 
  Patients receiving VSL  #  3 had a signifi  cant reduction in rectal 
bleeding (PP   P     =    0.014,  CI 95 %    0.46 – 0.70;  ITT   P     =    0.036,  CI 95 %    0.41 –
 0.65). On the other hand, we did not fi  nd any signifi  cant diff  erence 
in stool frequency (PP   P     =    0.202,  CI 95 %    0.39 – 0.63;  ITT   P     =    0.229, 
CI  95 %   0.35 – 0.57), physician ’ s rating of disease activity (PP  P     =    0.088, 
CI  95 %    0.34 – 0.58;  ITT   P     =    0.168,  CI 95 %    0.31 – 0.53),  or  mean  endo-
scopy scores (PP   P     =    0.086,  CI 95 %    0.74 – 0.92;  ITT   P     =    0.366,  CI 95 %   
0.66 – 0.86)  (see   Figure 3 ).   
  Safety and tolerability 
  No major adverse event was reported. Eight patients on VSL  #  3 
(11.2 % ) reported mild side eff  ects (one patient reported dizziness, 
one reported a fl  u-like syndrome, and six initially complained of 
abdominal bloating and discomfort), whereas nine patients on 
placebo (12.3  %  ) reported mild side eff  ects (one reported a fever, 
one had cystitis, three had abdominal bloating, and four patients 
had an unpleasant taste in their mouth).       
  DISCUSSION 
  UC is a chronic infl  ammatory disease of the colon involving still 
largely unknown interactions between genetic, environmental, 
and immunological factors. 
  UC is characterized by fl  are-ups of infl  ammation and periods 
of remission or quiescence that can be achieved or maintained by 
drugs having, as a common denominator, anti-infl  ammatory and  /
  or immunosuppressive properties (5-aminosalicylates, 6-mercap-
topurine, azathioprine, and anti-TNF  α   antibodies). If left   without 
any maintenance drug, about 70  %   of patients will relapse within 
12 months (  2  ), and many patients on maintenance drugs will still 
require step-up therapy. 
 Aft  er the initial report by Gionchetti   et al.   ( 3 )  on  pouchitis,  fol-
lowed by other confi  rmatory clinical studies, it is now accepted 
that VSL  #  3, a combination of probiotic bacteria, can place this 
disease in remission or quiescence in a large number of patients 
with a J-pouch, as recommended in the guidelines of international 
gastroenterological associations (  10,11  ). 
    Table 6  .       Reasons for discontinuation of treatment     
       
    VSL  #  3 number of 
patients (  %  )   
    Placebo number 
of patients (  %  )   
      Lack of efﬁ  cacy    0 (0.0)    5 (6.8) 
      Clinical episode    0 (0.0)    0 (0.0) 
      Abnormal laboratory result    0 (0.0)    0 (0.0) 
      Death   0 (0.0)    0 (0.0) 
      Protocol violation    2 (1.4)    0 (0.0) 
      Lost to follow-up    3 (4.2)    1 (1.4) 
      Protocol interim criteria not met    0 (0.0)    0 (0.0) 
      Patient  ’  s consent withdrawn    2 (2.8)    1 (1.4) 
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        Figure 2  .                 Percentage of patients with reduction of ulcerative colitis disease activity index (UCDAI) > 50  %   or of at least three points, and patients in 
remission at week 8 (on intention-to-treat analysis). n.s., not signiﬁ  cant.   The American Journal of GASTROENTEROLOGY  VOLUME 105 | OCTOBER 2010   www.amjgastro.com
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  Table 7  .       Overall UCDAI response after 8 weeks (per-protocol analysis)     
        UCDAI after 8 weeks       Treatment   
           VLS  #  3       Placebo       Overall   
           n         %         n         %         n         %     
      None or light (0   –   2)   31   47.7   23   32.4   54   39.7 
      Mild (3   –   5)   27   41.5   34   47.9   61   44.9 
      Moderate (6   –   8)   7   10.8   11   15.5   18   13.2 
      Severe (9   –  12)   0   0   3   4.2   3   2.2 
      Overall   65   100   71   100   136   100 
          UCDAI, ulcerative colitis disease activity index.     
  Table 8  .       Overall UCDAI response after 8 weeks (on intention-to-treat analysis)     
        UCDAI after 8 weeks       Treatment   
           VLS  #  3       Placebo       Overall   
           n         %         n         %         n         %     
      None or light (0   –   2)   31   43.7   23   31.5   54   37.5 
      Mild (3   –  5)   30   42.3   35   47.9   65   45.1 
      Moderate (6   –   8)   10   14.1   12   16.4   22   15.3 
      Severe (9   – 12)   0   0   3   4.1   3   2.1 
      Overall   71   100   73   100   144   100 
          UCDAI, ulcerative colitis disease activity index.     
0
10
20
30
40
50
60
Percentage of patients with reduction of rectal
bleeding at week 8
0
10
20
30
40
50
60
Percentage of patients with improvement
of stool frequency at week 8
VSL#3 Placebo
*
P=n.s. *P=0.036
0
5
10
15
20
25
30
35
40
45
50
Percentage of patients with improvement of
physician rating of disease activity at week 8
0
10
20
30
40
50
60
70
80
90
Percentage of patients with improvement of
endoscopic score at week 8
VSL#3 Placebo
VSL#3 Placebo VSL#3 Placebo
P=n.s. P=n.s.
    Figure 3  .                 Percentage of patients with improvement in different subgroups of ulcerative colitis disease activity index (UCDAI; rectal bleeding, stool 
frequency, physician rating of disease activity, and endoscopic score) at week 8 (on intention-to-treat analysis). n.s., not signiﬁ  cant.   © 2010 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Probiotics for Relapsing Ulcerative Colitis 
  We report the results of an Italian multicenter study aimed 
at evaluating the efficacy of the specific probiotic product, 
VSL  #  3, for the treatment of mild-to-moderate UC used in 
conjunction with standard treatment. Our study is a double-
blind randomized placebo-controlled trial on adult patients 
affected by relapsing mild-to-moderate UC, in which VSL  #  3 
or placebo was added to the standard treatment, and aimed 
to assess the decrease in UCDAI score of 50  %   or more. For 
ethical reasons, the   “  placebo  ”   group was a group in which the 
patients continued to take their standard treatment (5-ASA 
and  /  or immunosuppressant), with the simple addition of a 
placebo. 
 Overall,  VSL # 3  was  signifi  cantly superior to the placebo in 
reducing the activity of mild-to-moderate UC (primary end 
point). A signifi  cantly higher proportion of patients in the VSL # 3 
group experienced an improvement in their UCDAI score of 
at least 50  %   at week 8 over those who received placebo (63.1  %   
vs. 40.8  %  ,   P     =    0.010).  As  a  secondary  end  point,  31  individuals 
(47.7 % )  in  the  VLS # 3  group  and  23  individuals  (32.4 % )  in  the 
placebo group experienced remission by the end of 8 weeks, 
reaching results that did not show a signifi  cant diff  erence (PP 
  P     =    0.069;  ITT   P     =    0.132).  We  believe  that  this  might  represent  a 
type II error and that a larger study might have had enough power 
to detect a statistically signifi  cant diff  erence. None of the patients 
in the VSL  #  3 group experienced any worsening of symptoms 
during follow-up ( Tables 6 and 7 ), whereas fi  ve individuals in the 
placebo group showed a deterioration in their clinical status and 
had to be withdrawn from the study. No signifi  cant diff  erence 
in stool frequency, physician rating of disease activity, and mean 
endoscopy scores was detected between the two groups (  P     =      n.  s. 
(not signifi   cant)). However, VSL  #  3 patients had a signifi  cant 
reduction in rectal bleeding compared with the placebo group 
(PP   P     =    0.014;  ITT   P     =    0.036).  Finally,  no  major  adverse  event  was 
reported in either group. To confi  rm the effi   cacy of VSL  #  3, we 
also considered the patients who dropped out because of clinical 
ineff   ectiveness.  In  the   “ placebo ”   group,  fi  ve patients abandoned 
the study for this specifi  c reason (7 % ), whereas all VSL # 3 patients 
completed the study. 
 VSL # 3  has  proven  to  be  eff  ective by colonizing the host, chang-
ing the epithelial function and the immune response. Experimen-
tally, in murine models of colitis, VSL  #  3 prevents redistribution 
and reduced expression of sealing tight-junction proteins (  12  ) 
and specifi  cally stimulates the expression of genes associated with 
lipid, xenobiotic, and peroxisome proliferator-activated receptor 
signaling  ( 13 ). 
 Th   e roles of probiotics in managing active UC have also been 
reported in literature. Studies have reported   Escherichia coli   1917 
Nissle to be as eff  ective as low-dose mesalamine in preventing a 
relapse of quiescent UC   (14  –  16),   and treatment with   Saccharomyces 
boulardii   for 4 weeks was shown to induce clinical remission in 
71  %   of patients with mild-to-moderate disease; however, very few 
patients were enrolled to draw any conclusions (  17  ). Moreover, 
  S. boulardii   should be managed with caution, especially in immu-
nocompromised patients (e.g., in patients under immunosuppres-
sant treatment) (  18  ). 
  Other studies have reported the effi   cacy of VSL  #  3 in patients 
aff  ected by UC (  19  ). An open-label study (  20  ) showed that in 
5-ASA allergic or nonresponsive UC patients, VSL  #  3 was able 
to colonize the intestine and suggested that the product may be 
useful in maintaining remission (15 out of 20 patients remained 
in remission during the 1-year study). Th  ereaft  er, an open-label 
study found that 77  %   of mild-to-moderate UC patients obtained 
remission with 3,600 billion CFU  /  day of VSL  #  3 at 6 weeks (  6  ). An 
Italian randomized, controlled study found that VSL  #  3 900 billion 
CFU  /  day added to low-dose balsalazide shows better results in 
treating active UC than balsalazide or mesalazine alone (  5  ). Two 
studies with VSL # 3 in pediatric UC have recently been carried out; 
the fi  rst one is an open-label study showing that 56  %   of pediatric 
patients obtained remission, with a combined remission  /  response 
rate of 61  %   (  21  ), and the second one is a double-blind placebo-
controlled trial, showing that VSL  #  3 supplementation was only 
able to induce remission in 92.8  %   of UC children compared with 
36.4  %   with steroid alone, and was eff  ective in maintaining remis-
sion in 78.6  %   of patients during a 12-month follow-up compared 
with 26.7  %   in the placebo group (  22  ). 
  A recent Indian multicenter placebo-controlled trial investigat-
ing VSL  #  3 in mild-to-moderate UC patients was published (  23  ). 
Patients were given 3,600 billion CFU  /  day VSL  #  3 for 12 weeks. 
At week 6, the percentage of patients with an improvement in 
UCDAI  >50 %   was  signifi  cantly higher in the group given VSL  #  3 
(25, 32.5  %  ) than in the placebo group (7, 10  %  ;   P     =    0.001).  At  week 
12, 42.9  %   of VSL  #  3 patients achieved remission, compared with 
15.7 %   of  placebo  patients  ( P     <    0.001).  Furthermore,  signifi  cantly 
more number of patients given VSL  #  3 (40, 51.9  %  ) achieved a 
UCDAI decrease of more than three points, compared with those 
given placebo (13, 18.6  %  ;   P     <    0.001). 
  Although the design of our study was similar, we recorded 
a higher placebo response compared with the Sood   et al.  
(  23  ) study (40  %   in our trial vs. 10  %   in Indian trial). The high 
 “ placebo ”   response  rate  of  our  study  (40.8 %   of  placebo  patients 
had a 50 %  reduced UCDAI) may be easily explained by the con-
tinuous standard medical treatment provided to all the patients 
and allows for the statistically borderline results reached in this 
study for obtaining remission and mucosal healing. A possi-
ble suggestion for future studies, in addition to increasing the 
number of enrolled patients, may be to extend the study period 
to 12 weeks, expecting, as the Sood   et al.   ( 23 )  study  proved, 
that a longer treatment with VSL  #  3 will offer more divergence 
from the placebo group. As stated by a recent review, another 
possible explanation for this high   “  placebo  ”   response is that 
the country in which the study is conducted significantly 
influences the placebo response rate (  24  ). In particular, studies 
carried out exclusively in Europe have a significantly higher 
placebo remission rate than studies outside Europe, ranging 
from 20.8  %   to 33.6  %   (  24  ). Our placebo results are therefore in 
line with the literature estimates. This high percentage of pla-
cebo response may also account for some results of this study. 
For example, the failure to improve stool frequency vs. placebo 
may be very relevant to patients. We found VSL  #  3 better than 
placebo when we assessed the objective parameters (UCDAI, The American Journal of GASTROENTEROLOGY  VOLUME 105 | OCTOBER 2010   www.amjgastro.com
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system, competitive exclusion of proinflammatory pathogens, 
production of antimicrobial factors such as bacteriocins and 
other metabolites (  28,30  ), and support of increased intesti-
nal barrier function (  31,32  ). At present, on the basis of what 
has recently been published for acetaminophen, we cannot 
exclude the possibility that gut bacteria may be the principal 
target for drugs, and that by manipulating the gut flora in the 
drug treatment, the outcome can be improved (  33  ). 
  We do not know whether similar results could have been 
obtained only by increasing the 5-ASA daily dosage by up to 4 g, 
provided that the incidence of 5-ASA-related side eff  ects remains 
unchanged regardless of whether the dose is set at 2 g or 4 g. How-
ever, independent of any economic considerations (VSL # 3, being a 
probiotic, is not covered by insurance policies), we believe that the 
association between 5-ASA and VSL # 3 should be preferred, even to 
a high-dose 5-ASA regimen or to the  5-ASA / immunosuppressant 
association for the treatment of UC patients with mild-to-mod-
erate UC. Our opinion is based on the fact that, because the 
mammalian genome does not encode for all functions required 
for proper immunological responses, it is therefore evident that 
humans depend on critical interactions with their microbiome for 
health  ( 34,35 ). 
  In conclusion, our study found that the addition of the 
high-potency probiotic mixture VSL  #  3 to the standard UC 
treatment is able to induce significant symptomatic improve-
ment of relapsing mild-to-moderate UC compared with the 
placebo group on standard treatment only. This double-blind, 
placebo-controlled study found that VSL  #  3 is also able to 
improve the clinical picture, reduce symptoms, and improve 
the endoscopic appearance of the colonic mucosa. Therefore, 
VSL  #  3 may be considered as a safe and effective option for 
patients suffering from relapsing mild-to-moderate UC, to 
avoid or delay the administration of steroids, immunosup-
pressants, and biologics.     
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rectal bleeding, remission, and mucosal healing). On the con-
trary, subjective parameters (stool frequency and physician rat-
ing of disease activity) do not seem to improve so significantly 
under VSL  #  3 treatment. Two reasons may explain these con-
flicting results. First, the   “  placebo  ”   response may affect some 
subjective parameters (e.g., stool frequency). The second is 
that unchanged stool frequency may be related to overlapping 
irritable bowel syndrome, as this sometimes affects patients 
with inflammatory bowel disease (  25  ). 
  An important point of discussion to be addressed is the 
rationale of this study. People may argue that a higher dose of 
5-ASA therapy might be just as well tolerated and may be more 
convenient and less expensive for obtaining remission. Th  is 
may be a rational and advisable approach. However, we need 
a new therapeutic approach to relapsing UC, especially when 
the patient is already under treatment with immunosuppres-
sors. Increased doses of mesalazine formulations may be safe 
and eff  ective in obtaining remission, but the azo-bonded for-
mulations may be compromised by secretory diarrhea at doses 
providing  >2 – 2.4  g / day  of  mesalazine  ( 26 ).  Moreover,  biolog-
ics are at higher risk of severe side eff  ects and are much more 
expensive than a high-dose probiotic treatment in obtaining 
remission in relapsing UC. On the contrary, VSL  #  3 is classifi  ed 
as a food or food supplement in most countries and is char-
acterized by a very high safety profi  le that has also been con-
fi  rmed throughout this study. Th   e safety of VSL  #  3 has also been 
proven in pediatric infl  ammatory bowel disease and intensive 
care unit patients (  21,22,27  ). 
  Of course, once remission has been obtained, physicians also 
need to know how these patients should be managed in the longer 
term, i.e., with maintenance doses of probiotic. A clinical trial 
assessing the optimal dose of VSL  #  3 in maintaining remission of 
UC is needed. 
  Another criticism may be that the VSL  #  3 dose used in this 
study is quite high, compared with other studies reporting an 
effect on remission of UC or pouchitis (  7  ). This choice was 
based on the assumption that a high probiotic concentration 
is needed to treat an extensive and active colonic disease. Of 
course, the optimal dose to maintain remission may be much 
lower (e.g., one sachet daily for the maintenance of remis-
sion in pouchitis (  3  )), and, as stated, a further trial assessing 
the optimal dose of VSL  #  3 in maintaining remission of UC 
is needed. 
  In this trial, probiotics and 5-ASA seem to have a synergis-
tic activity. It is unclear how the association between probiotic 
and 5-ASA may take effect. It is possible that VSL  #  3 may func-
tion in synergy with, or perhaps increases, the anti-inflam-
matory action of 5-ASA compounds. 5-ASA compounds are 
potent inhibitors of several inflammatory mediators, such 
as leukotrienes, prostaglandins, and platelet-activating fac-
tor, all of which have roles in the pathogenesis of UC (  28  ). In 
addition, 5-ASA compounds inhibit the production of inter-
leukin-1 and free radicals and have an intrinsic antioxidant 
activity (  29  ). Probiotics reduce inflammation by a number 
of mechanisms, including alteration of the mucosal immune © 2010 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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 Study  Highlights 
    WHAT IS CURRENT KNOWLEDGE   
   3  Patients with ulcerative colitis (UC) may relapse even 
when under treatment. 
   3  If UC is already being treated with mesalazine and  /  or 
immunosuppressants, the next therapeutic step is represented 
by a further course of steroids or by the use of biologics. 
    WHAT IS NEW HERE   
   3  VSL  #  3 probiotic mixture seems to effect a signiﬁ  cant 
improvement in the clinical picture of patients with 
relapsing UC. 
   3  VSL  #  3 also seems to improve several other parameters, 
e.g., remission. 
   3  VSL  #  3 may be a useful tool in the treatment of relapsing 
UC in patients already under treatment with mesalazine 
and  /  or immunosuppressants, because humans depend on 
critical interactions with their microbiome for health  .                                
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